NASDAQ · Drug Manufacturers - General · USD
MIRA Pharmaceuticals, Inc. (MIRA) Stock Analysis
MIRA Pharmaceuticals, Inc. (MIRA) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
MIRA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.67
- Previous Close
- $0.65
- Day's Range
- 0.67–0.69
- 52-Week Range
- 0.60–1.80
- Volume
- 127.97K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.49
Valuation
- Market Cap
- $28.65M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.14
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$10.44M
- Shares Outstanding
- 42.02M
- 1-Year Return
- −52.98%
Dividend and dates
- Avg Volume
- 586.40K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, MIRA closed at $0.68, −52.98% over 1 year.
MIRA Pharmaceuticals, Inc. (MIRA) has a market capitalization of $28.65M.
In fiscal 2025, MIRA reported revenue of $0.00.
MIRA Stock Return by Calendar Year
MIRA Pharmaceuticals, Inc. (MIRA) return since Aug 2023: what $10,000 became
- 1 year
- $10,000 $4,702
- −52.98%
- 3 years
- $10,000 $2,185
- −78.15%
- Since Aug 2023
- $10,000 $919
- −90.81%
If you had invested $10,000 in MIRA Pharmaceuticals, Inc. (MIRA) at the close on August 3, 2023, the earliest close on record here, it would have been worth $919 at the close on October 21, 2026: −90.81% in total, −52.39% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −54.85% |
| 2025 | +32.46% |
| 2024 | +8.57% |
| 2023 (partial year) | −85.85% |
As of October 21, 2026.
MIRA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$10.44M | — |
| 2024 | $0.00 | −$7.85M | — |
| 2023 | $0.00 | −$11.98M | — |
| 2022 | $0.00 | −$7.06M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$10.49M | −$10.44M | — |
| 2024 | $0.00 | — | −$8.02M | −$7.85M | — |
| 2023 | $0.00 | — | −$8.53M | −$11.98M | — |
| 2022 | $0.00 | — | −$7.05M | −$7.06M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
YahooMaxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5
BenzingaMIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation
BenzingaWhy Is MIRA Pharmaceuticals Stock Gaining Tuesday?
BenzingaMIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - General Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
MRKMerck & Co., Inc.
$369.78B
NVSNovartis AG
$292.58B
AZNAstraZeneca PLC
$261.82B
Popular Healthcare Stocks
UnitedHealth Group Incorporated
$374.30B
TMOThermo Fisher Scientific Inc.
$256.61B
AMGNAmgen Inc.
$236.98B
GILDGilead Sciences, Inc.
$190.42B
ABTAbbott Laboratories
$173.92B